GENEVA, July 9 -- NOVOCURE GMBH filed a patent application (IB2023/063289) for “A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER”. With publication no. WO/2024/141952, here are the other details related to the patent application:
Kind: Correction of entry in Section I of the PCT Gazette [A8]
IPC: A61K 31/69
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....